Charles Sternberg, Associate Editor03.23.23
Companion Spine LLC, a French-American specialist in interventional spine pain-management surgery, has successfully closed a $60.1 million Series A funding round with a final closing of a $5.0 million top-off bringing the total in Series A to $60.1 million.
Formed by Viscogliosi Brothers, LLC in 2020, Companion Spine was created to address the two largest indications of the overall spine market: Lumbar Spinal Stenosis (LSS) and Degenerative Disc Disease (DDD), without the requirement of spine fusion surgery.
The company focuses on interventional spine pain treatment with revisable, minimally invasive, implants, focused on motion preservation, and precision diagnostics to allow for comprehensive spine health through offering a total spine care continuum approach for patients, spine pain specialists, treatment centers, and payors.
The completion of the Series A round will enable Companion Spine to successfully introduce both DIAM, Companion Spine’s main product, and LISA, the device obtained through the acquisition of the French company Backbone earlier in 2023, into new Global territories, accelerate worldwide sales growth, and advance the US FDA PMA submission process for the APERIUSTM and DIAMTM.
The top-off round was led by Viscogliosi Brothers, LLC (VB), Viscogliosi Brothers Watermark Holdings, LLC (VBW) and Epimed International, Inc (Epimed).
Erick Cloix, CEO and co-founder of Companion Spine, said: "The final closing of the capital raise supports our comprehensive solutions portfolio that precisely addresses, over time, the different stages and the multiple origins of back pain. Our unique portfolio of technologies enables interventional, earlier, safer, and scalable treatment to match the exact patient condition as it is today, or will be tomorrow, and after tomorrow.”
Anthony G. Viscogliosi, co-founder and Executive Chairman of Companion Spine and Principal at Viscogliosi Brothers, LLC, commented: "The VB investment philosophy is to skate where the puck will be, not where it is right now. This defines that VB invests in and leads new directions in healthcare.”
Mr. John J. Viscogliosi, Chairman of the Board of Viscogliosi Brothers Watermark Holdings, LLC, concluded: "We are excited to be a part of Companion Spine's already successful journey as we are committed to investing in the pioneering ventures of the neuromusculoskeletal space that are led by exceptional leadership without exception."
Formed by Viscogliosi Brothers, LLC in 2020, Companion Spine was created to address the two largest indications of the overall spine market: Lumbar Spinal Stenosis (LSS) and Degenerative Disc Disease (DDD), without the requirement of spine fusion surgery.
The company focuses on interventional spine pain treatment with revisable, minimally invasive, implants, focused on motion preservation, and precision diagnostics to allow for comprehensive spine health through offering a total spine care continuum approach for patients, spine pain specialists, treatment centers, and payors.
The completion of the Series A round will enable Companion Spine to successfully introduce both DIAM, Companion Spine’s main product, and LISA, the device obtained through the acquisition of the French company Backbone earlier in 2023, into new Global territories, accelerate worldwide sales growth, and advance the US FDA PMA submission process for the APERIUSTM and DIAMTM.
The top-off round was led by Viscogliosi Brothers, LLC (VB), Viscogliosi Brothers Watermark Holdings, LLC (VBW) and Epimed International, Inc (Epimed).
Erick Cloix, CEO and co-founder of Companion Spine, said: "The final closing of the capital raise supports our comprehensive solutions portfolio that precisely addresses, over time, the different stages and the multiple origins of back pain. Our unique portfolio of technologies enables interventional, earlier, safer, and scalable treatment to match the exact patient condition as it is today, or will be tomorrow, and after tomorrow.”
Anthony G. Viscogliosi, co-founder and Executive Chairman of Companion Spine and Principal at Viscogliosi Brothers, LLC, commented: "The VB investment philosophy is to skate where the puck will be, not where it is right now. This defines that VB invests in and leads new directions in healthcare.”
Mr. John J. Viscogliosi, Chairman of the Board of Viscogliosi Brothers Watermark Holdings, LLC, concluded: "We are excited to be a part of Companion Spine's already successful journey as we are committed to investing in the pioneering ventures of the neuromusculoskeletal space that are led by exceptional leadership without exception."
